drugset / Trial / NCT02859129

Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)

NCT02859129

Phase 1 Completed 114 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is intended to evaluate the potential 2-way reciprocal interaction between multiple doses of Epanova™ and a single dose of rosuvastatin

Timeline

Start
2013-09
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Epanova Other / unclassified 2 g Oral
Subject Epanova Other / unclassified 4 g Oral
Subject Rosuvastatin Small molecule 40 mg Oral
Comparator icosapent ethyl Small molecule 2 g Oral

Indications